查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1840754

甲状腺癌诊断市场按技术、样本类型、生物标记类型、应用和最终用户划分－2025-2032年全球预测

Thyroid Cancer Diagnostics Market by Technology, Sample Type, Biomarker Type, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，甲状腺癌诊断市场规模将成长 4.0784 亿美元，复合年增长率为 5.91%。

关键市场统计数据
基准年 2024 2.5758亿美元
预计年份：2025年 2.7314亿美元
预测年份 2032 4.0784亿美元
复合年增长率 (%) 5.91%

透过将临床需求、分子创新和诊疗路径中的实际操作相结合，建立甲状腺癌诊断需求框架

甲状腺癌诊断正处于曲折点，其驱动力源于临床需求、不断发展的分子科学以及整个医疗服务体系运作压力的交汇融合。本执行摘要的引言部分重点阐述了及时、准确且可操作的诊断资讯对于改善患者预后和製定标靶治疗策略至关重要的原因。随着临床医生和实验室负责人寻求减少诊断歧义并实现个体化治疗方案，诊断方式的评估不仅着眼于分析性能，还日益关注其与工作流程的兼容性、报销机制的契合度以及对后续临床的影响。

因此，支付方和医疗服务提供者越来越重视诊断结果的临床效用与获取结果所需资源之间的权衡，检体可及性、週转时间和与电子健康记录的整合等因素也日益受到关注。分子谱分析和辅助检测技术的进步正在拓展诊断范围，而不断更新的临床指引建议也在重塑检测流程。因此，相关人员必须权衡高解析度诊断数据的优势与病理学和实验室操作的实际限制，以确保创新能够转化为患者预后和系统效率的可衡量改善。

识别正在重塑甲状腺癌诊断方法开发、检验和部署方式的变革性技术、临床和报销驱动因素。

甲状腺癌的诊断模式正经历多重变革，这些变革正在改变患者的识别、分层和监测方式。首先，检测方法正从单一分析物检测转向整合遗传、表观遗传和蛋白质讯号的分子谱分析，实现更精细的风险分层。同时，诊断流程也变得更加贴近临床实际，微创采样技术和精简的实验室流程降低了重复检测和长期监测的门槛。

其次，科技的快速发展正在改变竞争动态。广泛应用的定序和数位PCR平台正日趋成熟，预计将实现大规模临床部署；而先进的免疫组织化学和灵敏的蛋白质检测技术则正在提升形态学和功能相关性。第三，监管机构和支付方日益严格的审查促使诊断技术开发人员更加重视临床验证和真实世界证据的产生。最后，数据互通性和分析软体正成为差异化优势，帮助临床医生将复杂的分子结果转化为可操作的治疗方案。综上所述，这些转变表明，成功的诊断策略需要将扎实的科学基础与切实可行的实证实施路径结合。

评估2025年关税如何改变了诊断製造商和实验室网路的采购、供应链弹性和定价。

2025年实施的定向关税和贸易措施引入了新的变量，影响诊断开发人员和实验室网路的采购、供应链韧性和资本配置。进口耗材和设备的到岸成本因关税增加而上升，迫使采购团队重新评估其供应商组合，尽可能加快本地供应商的资格认证，并重新评估高价值临床检测的定价策略。为此，仪器供应商和试剂生产商也重新评估了其销售模式和贸易条款，以缓解利润率压缩并维持市场进入。

在营运方面，采用集中采购模式的实验室正面临试剂前置作业时间和价格可预测性的不确定性，因此供应商多元化和库存优化具有重要的策略意义。同时，以创新为导向的机构正在探索本地製造伙伴关係和替代筹资策略，以应对未来贸易政策的波动。从临床营运角度来看，关税环境凸显了在控製成本与维持诊断准确性和周转时间之间取得平衡的必要性，促使各机构加强对特定流程简化和工作流程效率提升的投资。因此，相关人员应透过加强采购管治、检验二级供应商以及记录维持诊断品质的替代策略，为应对持续的贸易政策不确定性做好准备。

将技术、检体模式、生物标记类别、临床应用和最终用户与可操作的采纳路径和价值驱动因素联繫起来的多维度细分洞察

对诊断方式、检体类型、生物标记、应用和最终用户进行严格的细分，揭示了甲状腺癌诊断过程中不同领域的应用动态和临床价值提案。在技​​术方面，免疫检测仍然是蛋白质检测的主流方法，其中化学发光免疫分析和化学冷光免疫检测试验（ELISA）在不同形式中探索了不同的灵敏度-通量权衡；次世代定序应用于靶向测序、全外EXOME和全基因组测序，其覆盖范围和解读复杂度各不相同；即时PCR技术包括数字PCR和q22，可实现高靶向度和高峰值测量。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 高解析度超音波弹性成像技术在甲状腺结节表征方面的应用日益广泛
  • 将人工智慧演算法整合到超音波影像中，以提高甲状腺癌诊断的准确性
  • 分子基因表现分类器在不确定性甲状腺结节的准确风险分层中应用日益广泛
  • 对用于识别晚期甲状腺癌中可标靶突变的次世代定序的需求日益增长
  • 微创消融技术作为低风险乳突甲状腺肿瘤的治疗方法替代方案

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按技术分類的甲状腺癌诊断市场

  • 免疫检测
    • 化学冷光免疫检测
    • ELISA
  • 免疫组织化学
  • 次世代定序
    • 标靶定序
    • 全EXOME定序
    • 全基因组序列分析
  • 即时PCR
    • 数位PCR
    • 定量PCR

9. 甲状腺癌诊断市场（依样本类型划分）

  • 血液样本
  • 细针穿刺法
  • 组织切片检查

第十章 依生物标记类型分類的甲状腺癌诊断市场

  • 表观遗传标记
    • DNA甲基化
    • miRNA
  • 遗传标记
    • BRAF
    • RAS
    • TERT
  • 蛋白质标记物
    • 抑钙素
    • 甲状腺球蛋白

第十一章 依应用分類的甲状腺癌诊断市场

  • 诊断
  • 预后
  • 復发监测
  • 治疗监测

第十二章 甲状腺癌诊断市场（依最终用户划分）

  • 学术研究机构
    • 癌症研究中心
    • 大学研究实验室
  • 门诊治疗中心
    • 影像中心
    • 专科诊所
  • 诊断实验室
    • 连锁研究所
    • 独立研究机构
  • 医院
    • 私立医院
    • 公立医院

第十三章 各地区甲状腺癌诊断市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 甲状腺癌诊断市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国甲状腺癌诊断市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • F. Hoffmann-La Roche AG
    • Abbott Laboratories
    • Thermo Fisher Scientific Inc.
    • QIAGEN NV
    • Siemens Healthineers AG
    • Illumina Inc.
    • Hologic, Inc.
    • Danaher Corporation
    • Sysmex Corporation
    • bioMerieux SA
Product Code: MRR-A339DAEFAACE

The Thyroid Cancer Diagnostics Market is projected to grow by USD 407.84 million at a CAGR of 5.91% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 257.58 million
Estimated Year [2025] USD 273.14 million
Forecast Year [2032] USD 407.84 million
CAGR (%) 5.91%

Framing contemporary diagnostic imperatives in thyroid cancer by linking clinical needs with molecular innovation and operational realities across care pathways

Thyroid cancer diagnostics stand at an inflection point driven by a convergence of clinical needs, evolving molecular science, and operational pressures across healthcare delivery systems. The introductory context for this executive summary emphasizes why timely, accurate, and actionable diagnostic information is now central to improving patient trajectories and enabling targeted therapeutic decisions. As clinicians and laboratory leaders seek to reduce diagnostic ambiguity and to personalize care pathways, diagnostic modalities are being evaluated not only for analytical performance but also for workflow compatibility, reimbursement alignment, and downstream clinical impact.

Consequently, payers and providers increasingly weigh the clinical utility of a diagnostic result against the resources required to produce it, which elevates considerations such as sample accessibility, turnaround time, and integration with electronic health records. Advances in molecular profiling and ancillary assays have broadened the diagnostic window, while evolving clinical guideline recommendations are reshaping testing algorithms. Therefore, stakeholders must reconcile the promise of high-resolution diagnostic data with pragmatic constraints within pathology and laboratory operations, to ensure that innovations translate into measurable improvements in patient outcomes and system efficiencies.

Identifying the transformative technological, clinical, and reimbursement-driven shifts that are reshaping how thyroid cancer diagnostics are developed, validated, and deployed

The landscape of thyroid cancer diagnostics is being transformed by several concurrent shifts that are altering how patients are identified, stratified, and monitored. First, there is a palpable shift from single-analyte assays toward integrated molecular profiles that combine genetic, epigenetic, and protein signals, enabling more nuanced risk stratification. At the same time, diagnostic workflows are moving closer to real-world clinical use: less invasive sampling techniques and streamlined laboratory processes are lowering barriers to repeat testing and longitudinal monitoring.

Second, technological diffusion is changing competitive dynamics. Widely adopted platforms for sequencing and digital PCR have reached a level of operational maturity that allows for scaled clinical deployment, while refined immunohistochemistry and high-sensitivity protein assays are improving morphological and functional correlation. Third, regulatory and payer scrutiny is increasing, prompting diagnostics developers to place greater emphasis on clinical validation and real-world evidence generation. Finally, data interoperability and analytic software are emerging as differentiating capabilities, because they enable clinicians to transform complex molecular outputs into actionable treatment pathways. Together, these shifts indicate that successful diagnostics strategies will be those that combine robust science with practical, evidence-based implementation pathways.

Assessing how 2025 tariff measures have reshaped procurement, supply chain resilience, and pricing considerations across diagnostic manufacturers and laboratory networks

The introduction of targeted tariffs and trade measures in 2025 has introduced new variables that influence sourcing, supply chain resilience, and capital allocation across diagnostic developers and laboratory networks. Tariff-related increases in the landed cost of imported consumables and instrumentation have prompted procurement teams to reassess supplier portfolios, accelerate qualification of local vendors where possible, and re-evaluate pricing strategies for high-value clinical tests. In response, instrument vendors and reagent manufacturers have revisited distribution models and commercial terms to mitigate margin compression and to preserve market access.

Operationally, laboratories with centralized procurement have experienced variability in reagent lead times and pricing predictability, which has elevated the strategic importance of supplier diversification and inventory optimization. Meanwhile, innovation-oriented organizations are exploring local manufacturing partnerships and alternative sourcing strategies to buffer against future trade policy volatility. From a clinical operations perspective, the tariff environment has underscored the need to balance cost containment with maintaining diagnostic fidelity and turnaround time, driving selective protocol rationalization and greater investment in workflow efficiencies. As a result, stakeholders should plan for ongoing trade policy uncertainty by strengthening procurement governance, validating secondary suppliers, and documenting substitution strategies that preserve diagnostic quality.

A multidimensional segmentation insight that links technologies, specimen modalities, biomarker classes, clinical applications, and end users to practical adoption pathways and value drivers

A rigorous segmentation-based view of diagnostic modalities, sample types, biomarkers, applications, and end users reveals differentiated adoption dynamics and clinical value propositions across the thyroid cancer diagnostic continuum. Based on Technology, immunoassay remains a mainstay for protein detection and is examined through its chemiluminescence immunoassay and ELISA formats, which offer differing trade-offs in sensitivity and throughput; immunohistochemistry provides pathologic context at the tissue level; next generation sequencing is implemented across targeted sequencing, whole exome sequencing, and whole genome sequencing approaches that vary in breadth and interpretive complexity; and real time PCR technologies include both digital PCR and qPCR platforms that enable sensitive quantitation and targeted mutation detection.

Based on Sample Type, diagnostic pathways rely on blood sample testing for minimally invasive biomarker capture, fine needle aspiration for cytologic evaluation in ambulatory settings, and tissue biopsy for comprehensive histopathologic and molecular assessment. Based on Biomarker Type, the portfolio spans epigenetic markers such as DNA methylation and microRNA signatures, genetic markers including BRAF, RAS, and TERT alterations, and protein markers exemplified by calcitonin and thyroglobulin measurements, each contributing unique diagnostic or prognostic information. Based on Application, testing is organized around diagnosis, prognosis, recurrence monitoring, and therapy monitoring, reflecting the longitudinal needs of clinicians managing thyroid neoplasia. Finally, based on End User, the ecosystem ranges from academic research institutes-encompassing cancer research centers and university laboratories-to ambulatory care centers that include imaging centers and specialized clinics, diagnostic laboratories comprised of chain and independent operators, and hospitals differentiated between private and public facilities, each with distinct procurement, operational, and clinical integration requirements. Taken together, this segmentation highlights how technology choice, specimen accessibility, biomarker selection, clinical purpose, and institutional context collectively determine the design and adoption pathway for diagnostic solutions.

Regional diagnostic ecosystems and adoption dynamics across the Americas, Europe, Middle East & Africa, and Asia-Pacific that determine access, validation, and clinical integration

Regional dynamics exert a pronounced influence on diagnostic access, regulatory interpretation, and adoption pathways, and insights differ meaningfully across the principal geographies of interest. In the Americas, there is a high level of clinical integration between molecular testing and therapeutic decision-making, supported by advanced laboratory infrastructure and established reimbursement frameworks that favor tests with demonstrated clinical utility. This environment fosters rapid uptake of next generation sequencing panels and highly sensitive protein assays, while also encouraging partnerships between diagnostic developers and large laboratory networks to scale deployment.

In Europe, Middle East & Africa, heterogeneity in regulatory regimes and health system financing yields a more fragmented adoption picture. Certain countries emphasize centralized reference laboratory models and prioritize cost-effectiveness assessments, while others are more permissive toward decentralized testing in ambulatory settings. Across this region, efforts to harmonize nomenclature, reporting standards, and cross-border data sharing are progressing, enabling broader collaborative studies and validation initiatives. In the Asia-Pacific region, investment in diagnostic infrastructure and domestic manufacturing capacity has accelerated, supporting both the local development of assays and rapid clinical uptake in tertiary centers. The region also exhibits a strong appetite for point-of-care solutions and streamlined workflows that address high patient volumes. Across all geographies, regulatory alignment, reimbursement clarity, and supply chain robustness remain decisive factors that shape how diagnostic innovations move from pilot programs to standard clinical practice.

Competitive and collaborative forces among assay developers, platform providers, laboratories, and data vendors that define strategic differentiation and partnership opportunities

Competitive dynamics among diagnostic companies, laboratory networks, and technology providers are increasingly characterized by strategic specialization, platform consolidation, and partnerships that bridge clinical and data capabilities. Leading product strategies emphasize robust clinical validation packages, workflow-friendly instruments, and integrated bioinformatics that translate complex outputs into clinician-ready reports. Companies pursuing differentiation are investing in assay standardization, external quality programs, and physician engagement to demonstrate reproducible clinical utility across diverse patient cohorts.

At the same time, partnership models are expanding: collaborations between assay developers and academic centers facilitate clinical validation and guideline adoption, while alliances with laboratory networks enable scale and geographic reach. Instrument vendors that offer holistic solutions-including sample-to-answer systems, reagent continuity programs, and analytics-are gaining traction with high-volume end users. Emerging players focused on point-of-care devices, AI-driven interpretation, and biomarker discovery are attracting attention, but they must navigate regulatory pathways and demonstrate clinical impact. For stakeholders evaluating potential partners or competitors, the ability to integrate into existing laboratory information systems, to provide clear value propositions for clinicians, and to sustain supply chain reliability will determine success in this evolving landscape.

Actionable strategic recommendations for diagnostics leaders to align clinical validation, supply resilience, payer engagement, and cross-functional commercial execution

Industry leaders should pursue a coordinated set of actions that align technological innovation with clinical validation and operational scalability, thereby accelerating the translation of diagnostic advances into routine care. First, prioritize the generation of robust clinical evidence that links diagnostic outputs to actionable treatment decisions and patient outcomes, and ensure that study designs reflect real-world sample types and workflow constraints. Second, design products and services with interoperable reporting and clinician-friendly interpretive guidance to reduce cognitive load during decision-making and to facilitate adoption across diverse care settings.

Third, strengthen supply chain resilience through multi-source procurement, local manufacturing partnerships where feasible, and contractual commitments for reagent continuity to mitigate the impact of trade volatility. Fourth, engage early with payers and health technology assessment bodies to clarify evidence requirements and establish pathways for reimbursement or value-based contracting. Fifth, invest in partnerships with academic centers and reference laboratories to accelerate validation, develop training programs for pathologists and clinicians, and to create credible clinical champions. Finally, build flexible commercial models that accommodate variable purchasing preferences across academic research institutes, ambulatory care centers, diagnostic laboratories, and hospitals, ensuring alignment with each end user's operational and financial constraints. Executing these priorities will require cross-functional coordination across R&D, regulatory, clinical affairs, supply chain, and commercial teams.

A transparent and evidence-focused research methodology combining literature review, expert interviews, and analytical triangulation to validate clinical and operational diagnostic insights

The research methodology underpinning this executive summary combines structured literature synthesis, targeted expert engagement, and pragmatic synthesis of operational insights to produce actionable conclusions. Primary inputs include peer-reviewed scientific literature on thyroid oncology diagnostics, clinical guideline statements, regulatory documents, and white papers that elucidate analytical and clinical performance characteristics. These sources are complemented by semi-structured interviews with clinicians, laboratory directors, and senior diagnostic executives to surface real-world operational constraints and adoption rationales.

Analytical triangulation was applied to reconcile divergent perspectives, emphasizing cross-validation between clinical utility narratives and laboratory workflow realities. Where possible, technical performance claims for assay platforms were evaluated against published validation studies and proficiency testing outcomes. Key limitations of the methodology include variability in reporting standards across studies and differential availability of real-world evidence for newer technologies. To mitigate these limitations, the approach prioritized high-quality evidence, transparent documentation of assumptions, and iterative validation with subject-matter experts to ensure that conclusions are both relevant and implementable for stakeholders across clinical, laboratory, and commercial functions.

Synthesis and closing insights that emphasize the need for utility-driven innovation, workflow integration, and supply chain resilience to realize diagnostic value in clinical practice

In conclusion, thyroid cancer diagnostics are evolving from discrete assays toward an integrated ecosystem in which molecular profiles, histopathology, and advanced protein testing jointly inform patient management. Progress in sequencing, digital PCR, immunoassays, and interpretive analytics is expanding clinical options, while operational realities such as sample type, laboratory capacity, and procurement constraints influence which innovations are adoptable at scale. Trade policy shifts and regional heterogeneity further underscore the need for adaptable commercialization and supply strategies.

Ultimately, success in this space will be determined by the degree to which diagnostic developers and laboratory operators can demonstrate clinical utility, ensure seamless workflow integration, and maintain supply chain reliability. By aligning product design with clinician needs, regulatory expectations, and end-user operational realities, stakeholders can accelerate the transition of promising technologies from pilot validation to routine clinical use, thereby improving diagnostic precision and patient care pathways across varied healthcare settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing adoption of high-resolution ultrasound elastography for improved thyroid nodule characterization
  • 5.2. Integration of artificial intelligence algorithms in ultrasound imaging to enhance diagnostic accuracy in thyroid cancer
  • 5.3. Growing utilization of molecular gene expression classifiers for precise risk stratification in indeterminate thyroid nodules
  • 5.4. Rising demand for next-generation sequencing panels to identify actionable mutations in advanced thyroid carcinoma
  • 5.5. Emergence of minimally invasive ablation techniques as alternative therapies for low-risk papillary thyroid tumors

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Thyroid Cancer Diagnostics Market, by Technology

  • 8.1. Immunoassay
    • 8.1.1. Chemiluminescence Immunoassay
    • 8.1.2. ELISA
  • 8.2. Immunohistochemistry
  • 8.3. Next Generation Sequencing
    • 8.3.1. Targeted Sequencing
    • 8.3.2. Whole Exome Sequencing
    • 8.3.3. Whole Genome Sequencing
  • 8.4. Real Time PCR
    • 8.4.1. Digital PCR
    • 8.4.2. qPCR

9. Thyroid Cancer Diagnostics Market, by Sample Type

  • 9.1. Blood Sample
  • 9.2. Fine Needle Aspiration
  • 9.3. Tissue Biopsy

10. Thyroid Cancer Diagnostics Market, by Biomarker Type

  • 10.1. Epigenetic Markers
    • 10.1.1. DNA Methylation
    • 10.1.2. miRNA
  • 10.2. Genetic Markers
    • 10.2.1. BRAF
    • 10.2.2. RAS
    • 10.2.3. TERT
  • 10.3. Protein Markers
    • 10.3.1. Calcitonin
    • 10.3.2. Thyroglobulin

11. Thyroid Cancer Diagnostics Market, by Application

  • 11.1. Diagnosis
  • 11.2. Prognosis
  • 11.3. Recurrence Monitoring
  • 11.4. Therapy Monitoring

12. Thyroid Cancer Diagnostics Market, by End User

  • 12.1. Academic Research Institutes
    • 12.1.1. Cancer Research Centers
    • 12.1.2. University Laboratories
  • 12.2. Ambulatory Care Centers
    • 12.2.1. Imaging Centers
    • 12.2.2. Specialized Clinics
  • 12.3. Diagnostic Laboratories
    • 12.3.1. Chain Laboratories
    • 12.3.2. Independent Laboratories
  • 12.4. Hospitals
    • 12.4.1. Private Hospitals
    • 12.4.2. Public Hospitals

13. Thyroid Cancer Diagnostics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Thyroid Cancer Diagnostics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Thyroid Cancer Diagnostics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. F. Hoffmann-La Roche AG
    • 16.3.2. Abbott Laboratories
    • 16.3.3. Thermo Fisher Scientific Inc.
    • 16.3.4. QIAGEN N.V.
    • 16.3.5. Siemens Healthineers AG
    • 16.3.6. Illumina Inc.
    • 16.3.7. Hologic, Inc.
    • 16.3.8. Danaher Corporation
    • 16.3.9. Sysmex Corporation
    • 16.3.10. bioMerieux S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. THYROID CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. THYROID CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. THYROID CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY QPCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY QPCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY QPCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY QPCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY QPCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY QPCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD SAMPLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD SAMPLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD SAMPLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD SAMPLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD SAMPLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD SAMPLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DNA METHYLATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DNA METHYLATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DNA METHYLATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DNA METHYLATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DNA METHYLATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DNA METHYLATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY MIRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY MIRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY MIRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY MIRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY MIRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY MIRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BRAF, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BRAF, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BRAF, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BRAF, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BRAF, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BRAF, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY RAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY RAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY RAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY RAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY RAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY RAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TERT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TERT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TERT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TERT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TERT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TERT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CALCITONIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CALCITONIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CALCITONIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CALCITONIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CALCITONIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CALCITONIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY THYROGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY THYROGLOBULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY THYROGLOBULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY THYROGLOBULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY THYROGLOBULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY THYROGLOBULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY RECURRENCE MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY RECURRENCE MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY RECURRENCE MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY RECURRENCE MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY RECURRENCE MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY RECURRENCE MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY THERAPY MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY THERAPY MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY THERAPY MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY THERAPY MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY THERAPY MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY THERAPY MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CANCER RESEARCH CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CANCER RESEARCH CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CANCER RESEARCH CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CANCER RESEARCH CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CANCER RESEARCH CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CANCER RESEARCH CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY UNIVERSITY LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY UNIVERSITY LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY UNIVERSITY LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY UNIVERSITY LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY UNIVERSITY LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY UNIVERSITY LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CHAIN LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CHAIN LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CHAIN LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CHAIN LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CHAIN LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY CHAIN LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARK